14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHCO vs IRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IRMD carries 42.0/100 (HOLD) at $81.02 (33.2x Forward P/E, 32.3% operating margin).
Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IRMD 42.0/100 HOLD), IRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (32.3% vs. 3.8% operating margin) and revenue trajectory (+14.2% vs. +10.9% YoY).
Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment14.4% of Rev ($495M)
90D Engineering Disclosures0 Published
IRMD Moat ProfileHigh-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $1.0B market capitalization and 32.3% operating margin.
OpEx & R&D Reinvestment43.2% of Rev ($39M)
90D Engineering Disclosures0 Published
Investor FAQ AHCO vs IRMD Key Questions & Quantitative Answers
As of Nov 20, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IRMD carries 42.0/100 (HOLD) at $81.02 (33.2x Forward P/E, 32.3% operating margin). Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IRMD 42.0/100 HOLD), IRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (32.3% vs. 3.8% operating margin) and revenue trajectory (+14.2% vs. +10.9% YoY). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IRMD leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with IRMD at +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while IRMD shifted +166.7%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 43.2% of Rev ($39M) (0 disclosures) for IRMD.
AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas IRMD trades at 33.2x Forward P/E, 43.5x Trailing P/E, 4.46x PEG, and 11.6x EV/Revenue (28.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus IRMD (23.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, IRMD carries 37.2% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.